Generics in antiepileptic drug therapy: What has to be considered?;Generika in der epilepsietherapie: Was ist zu beachten?

Aktuelle Neurologie

Volumn 32, Issue 5, 2005, Pages 275-278

  Krämer, Günter ^a   Dennig, D ^b   Schmidt, D ^c   Schmitz, B ^d   Stefan, H ^e   Steinhoff, B J ^f   Stephani, U ^g   Stodieck, S ^h  

^a SWISS EPILEPSY CENTER   (Switzerland)

^b Neurologische Praxis   (Germany)

^c Forschungsgruppe Epilepsie   (Germany)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^f Epilepsiezentrum Kehl Kork   (Germany)

^g UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^h Epilepsiezentrum Hamburg   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; GABAPENTIN; GENERIC DRUG; LAMOTRIGINE; VALPROIC ACID;

ANTICONVULSANT THERAPY; DRUG EFFICACY; DRUG TOLERABILITY; EPILEPSY; EPILEPTOGENESIS; GERMANY; HUMAN; MEDICAL SOCIETY; PRESCRIPTION; PROBLEM SOLVING; RECURRENCE RISK; REVIEW; SEIZURE;

EID: 21344447275     PISSN: 03024350     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2005-866893     Document Type: Review

References (13)

1. Schwabe U, Pfaffrath D (Hrsg). Arzneiverordnungsreport 2004. Berlin, Heidelberg, New York et al.: Springer, 2004: 14-15
2. Krämer C, Schneble H, Wolf P. Risiken der neuen Aut-idem-Regelung für die Behandlung mit Antiepileptika. Akt Neurol 2002; 29: 115-122
3. Blume H, Brauer KC, Dingermann T et al. Gute Substitutionspraxis - GSP. Dtsch Apoth Ztg 2002; 142: 1205-1214
4. Blier P. Brand versus generic medications: the money, the patient and the research. J Psychiat Neurosci 2003; 28: 167-168
5. Cuberman A, Corman C. Generic substitution for brand name antiepileptic drugs: a survey. Can J Neurol Sci 2000; 27: 37-43
6. Wilner AN. Physicians underestimate the frequency of generic carbamazepine substitution: results of a survey and review of the problem. Epilepsy & Behavior 2002; 3: 522-525
7. Wilner AN. Therapeutic equivalence of generic antiepileptic drugs: results of a survey. Epilepsy & Behavior 2004; 5: 995-998
8. Crawford P, Feely M, Guberman A, Krämer G. Are there potential problems with generic substitution of antiepileptic drugs? A review of issues. Submitted
9. The European Agency for the Evaluation of Medicinal Products (Evaluation of Medicines for Human Use). Committee for Proprietary Medicinal Products (CPMP). Note for guidance on the Investigation of bioavailability and bioequivalence. London: EMEA, 2001, www.eudra. org/emea.html
10. Meredith PA. Generic drugs. Therapeutic equivalence. Drug Safety 1996; 15: 233-242
11. Wemhöner G, Frehse M. Haftungsrechtliche Aspekte bei der ärztlichen Arzneimittelverordnung und Arzneimittelanwendung. Dtsch Med Wchschr 2004; 129: 327-329
12. Schmidt D, Steinhoff BJ, Krämer G et al. Juristische Aspekte der Epilepsiebehandlung: ärztliche Fehler. Nervenheilkunde, 2005; 24: im Druck
13. Jobst BC, Holmes GL Prescribing antiepileptic drugs. Should patients be switched on the basis of cost? CNS Drugs 2004; 18: 617-628